FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BOGER JOSHUA S							2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								tionship of all applications all applications all applications are all a	able)	g Pers	son(s) to Iss 10% Ov	
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED						3. Date of Earliest Transaction (Month/Day/Year) 09/03/2008								X	Officer (give title below) President & CEO				
130 WAVERLY STREET (Street) CAMBRIDGE MA 02139					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								. Indivine)	ridual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S		(Zip)																
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day)					ction	on 2A. Deemed Execution Date,			3. Transaction Code (Instr. 8)		4. Securities Disposed O	l (A) or	5. Amount of		nt of es ally Following	Forn (D) o	n: Direct or Indirect nstr. 4)	Ownership	
							Code	v	Amount	(A) or (D)	Price	Trans		etion(s) and 4)			(Instr. 4)		
Common Stock 09/03/2					2008	08			М		12,400	A	\$10.	1,107,444		7,444		D	
Common Stock 09/03/2					2008	308			S ⁽¹⁾		12,400	D	\$25.93(2)(3)		1,095,044			D	
Common Stock															12	,445		I	401(k)
Common Stock															207	7,500			Shares in trust ⁽⁴⁾
		-	Table II								posed of, , converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deel Execution if any (Month/I		4. Transa Code (8)				6. Date Exerc Expiration Da (Month/Day/\)		ate	7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		rity (In	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amour or Numbe of Shares	umber					
Stock	\$10.19	09/03/2008			М			12.400	(5)		09/16/2008	Common	1 12 40	۸۱	ΦΩ	12 779	,	_ n	1

Explanation of Responses:

- 1. Transaction for sales of common stock made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$25.93 (range \$25.47 to \$26.43).
- 3. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Shares held in trust for Dr. Boger's children. Dr. Boger disclaims beneficial ownership of such shares.
- 5. Fully vested.

Remarks:

Valerie L. Andrews, Attorney-

09/04/2008

In-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.